Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Both the U.S. label and UCSF use indexed eGFR for this combination. Their printed renal-band boundaries differ: the UCSF bands overlap at 30 and place 50 in a different printed band. Retain the selected source boundary explicitly; do not treat an overlap as an instruction to combine regimens.
Check source scope before reading a dose
UCSF: meropenem/vaborbactam renal and dialysis tables
Product / population
UCSF adult institutional all-indications table; not a replacement for exact labeled indication and boundaries.
Renal method
Indexed eGFR in mL/min/1.73 m2; intermittent and continuous hemodialysis.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Renal-band endpoints differ between the label mirror and UCSF
Both tables use indexed eGFR, but the label assigns exactly 50 to its full-dose band, whereas UCSF prints >50 and 30-50. UCSF also prints overlapping bands at exactly 30. The dialysis and indication scopes are separately stated.
What to reconcile: Do not silently round an estimate, substitute unindexed CrCl, average doses, or combine one source's band with another interval. Clarify boundary cases with the applicable label and institutional antimicrobial team.
UCSF Infectious Diseases Management Program · UCSF adult institutional all-indications table; not a replacement for exact labeled indication and boundaries.
Renal method: Indexed eGFR in mL/min/1.73 m2; intermittent and continuous hemodialysis. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The displayed eGFR bands are >50, 30-50, 15-30 and <15. Corresponding combined doses are 4 g every eight hours, 2 g every eight hours, 2 g every twelve hours and 1 g every twelve hours, each IV over three hours. Exactly 30 overlaps two source rows; exactly 50 also differs from the label boundary. Intermittent HD uses 1 g every twelve hours with one dose after HD on dialysis days. Continuous HD uses 2 g every eight hours. Restricted specialist use is specified. Do not silently round or merge source boundaries.
RDM40-professional-meropenem-vaborbactam-f6a38d7cf6-C1 · Source locator: Adult eGFR table and intermittent/continuous-HD table
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.